Abstract
The teratogenic consequences of angiotensin-converting enzyme inhibitors angiotensin receptor blockers (ARBs) during the second and third trimesters of pregnancy are well described. However, the consequences of exposure during the first trimester are unclear, especially in diabetes. We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy.
Original language | English |
---|---|
Journal | Diabetologia |
Volume | 54 |
Issue number | 6 |
Pages (from-to) | 1298-303 |
Number of pages | 6 |
ISSN | 0012-186X |
DOIs | |
Publication status | Published - 2011 |
Keywords
- Abnormalities, Drug-Induced
- Adolescent
- Adult
- Angiotensin Receptor Antagonists
- Benzimidazoles
- Diabetes Mellitus, Type 1
- Diabetic Retinopathy
- Female
- Humans
- Hypertension
- Pregnancy
- Pregnancy Complications, Cardiovascular
- Pregnancy Outcome
- Pregnancy Trimester, First
- Risk Factors
- Tetrazoles
- Young Adult